Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced XXXX improves resectability.

@entity1 @entity788 @entity137 @entity416 @entity5 @entity3 @entity136
BACKGROUND AND OBJECTIVES: Though necessary for improved outcomes, surgical resection is often limited in @entity1 with locally advanced @entity788 (LAPCs). We evaluated the efficacy of the approach adopted by our institution of using modified FOLFIRINOX chemotherapy followed by radiation with concurrent @entity136 or @entity416 for @entity1 with LAPCs, in an effort to enhance resectability while improving the @entity137 profile compared with similar treatment regimens. METHODS: We included 29 consecutive @entity1 with LAPC treated at our institution with the above approach in this review. We evaluated rates of resection, locol control, and survival outcomes in this cohort. RESULTS: The median follow up for this series of @entity1 was 15.2 months. Approximately half the @entity1 were unresectable at presentation. After neoadjuvant therapy, 41.3% of all @entity1 were able to undergo resection of their @entity5 and 83% achieved an R0 resection. One-year local control for the entire cohort was 85%; one-year progression-free and overall were 49.2% and 65.5%, respectively. High rates of @entity3 were seen regardless of resectability. There were minimal @entity137 in this cohort. CONCLUSIONS: Neoadjuvant therapy with induction modified FOLFIRINOX and chemoradiation presents a well-tolerated, promising treatment approach for @entity1 with LAPC. High rates of @entity3 highlight the need to optimize systemic and targeted agents for @entity788 . J. Surg. Oncol. 2015 111:1028-1034.    2015 Wiley Periodicals, Inc.
